tirzepatide and fainting vs. Semaglutide for Weight Loss Compounded Tirzepatide

Tirzepatide also demonstrated favorable effects on lipid profiles, blood pressure, and biomarkers of insulin sensitivity and liver function.The most common adverse events reported with tirzepatide and semaglutide were gastrointestinal in nature, including nausea, diarrhea, and vomiting, which were mostly mild to moderate in severity

Patients experiencing this symptom should consider both medication-related and independent gastrointestinal causes, particularly if mucus is accompanied by other concerning features such as blood, significant abdominal pain, or persistent changes in bowel habits

Across the SURPASS trials documented in the Mounjaro FDA prescribing information, injection-site reactions occurred in approximately 3-7% of participants depending on dose, while true systemic allergic responses (hives spreading beyond the site, facial swelling, breathing difficulty) are rare

Pricing, program features, eligibility criteria, policies, and the federal regulatory framework for compounded GLP-1 medications are subject to change